Adjuvant trastuzumab for breast cancer: Assessing HER2/neu status incurs more costs for treatment
- 17 November 2005
- Vol. 331 (7526) , 1202.1-1202
- https://doi.org/10.1136/bmj.331.7526.1202
Abstract
EDITOR—The results of recent trials are likely to continue to fuel the demand for trastuzumab in the adjuvant setting of early breast cancer,1 as well as a possible neoadjuvant treatment in the near future. …Keywords
This publication has 3 references indexed in Scilit:
- Adjuvant trastuzumab for breast cancerBMJ, 2005
- Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical TrialsClinical Cancer Research, 2005
- The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of TherapyThe Oncologist, 2003